Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SM17 Monoclonal Antibody Injection (Subcutaneous) in Chinese Healthy Participants

Next Previous
Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SM17 Monoclonal Antibody Injection (Subcutaneous) in Chinese Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SM 17 (Primary) ; SM 17
  • Indications Asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases
  • Focus Therapeutic Use
  • Sponsors SinoMab Bioscience Ltd

Most Recent Events

  • 06 Apr 2026 Actual primary completion date changed from 5 Feb 2026 to 3 Feb 2026.
  • 06 Apr 2026 Status changed from active, no longer recruiting to completed.
  • 17 Mar 2026 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top